Trial results

The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus

NCT03239119 on ClinicalTrials.gov · last registry update 2017-08-03

456 participants. Its estimated completion date, 30 December 2018, has passed with no update to the record. Primary outcome, as filed: Change in HbA1c from Baseline to Week 30. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

UNKNOWN

Phase

P3

Drug

exenatide

Bydureon, Byetta

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Sponsor type

Industry

Enrollment

456

Started

2017-11-30

Primary completion

2018-12-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c from Baseline to Week 30

Conditions studied

Type2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.